NR3C2 and myocardial infarction: When compared to the older aldosterone receptor blocking agent spironolactone, Eplerenone has higher affinity for aldosterone receptor and much less affinity for progesterone receptors (<1%) and androgen receptors (0.1%).20 Recent animal trials have shown that eplerenone reduces the extent of necrosis in myocardial infarction also reduces arteriopathy in hypertensive and heart failure patients.21